Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  radium Ra 223 dichloride
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-10 of 10 for your search:
Start Over
A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 15245, BC1-06, NCT00699751
Radium(223) Dichloride (Alpharadin) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 16216, 2012-000075-16, NCT01618370
A Study of Alpharadin With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer (CRPC)
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 15469, BC1-10, NCT01106352
Re-treatment Safety of Radium-223 Dichloride in Castration-resistant Prostate Cancer With Bone Metastases
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 16506, 2013-003046-17, NCT01934790
BAY88-8223, Dose Finding Study in Patients With HRPC
Phase: Phase II
Type: Treatment
Status: Completed
Age: No age specified
Sponsor: Pharmaceutical / Industry
Protocol IDs: 15304, 2005-003680-22, BC1-04, NCT00337155
BAY88-8223, Alpharadin, Breast Cancer Patients With Bone Dominant Disease
Phase: Phase II
Type: Treatment
Status: Completed
Age: Any age
Sponsor: Pharmaceutical / Industry
Protocol IDs: 15468, 2009-012189-30, BC1-09, NCT01070485
Japanese BAY88-8223 Monotherapy Phase II Study
Phase: Phase II
Type: Treatment
Status: Closed
Age: 20 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 16430, NCT01929655
Alpharadin™ (Radium-223 Chloride) Safety and Dosimetry With HRPC That Has Metastasized to the Skeleton
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 15303, BC1-08, NCT00748046
Safety, Biodistribution, Radiation Dosimetry and Pharmacokinetics Study of BAY88-8223 in Japanese Patients
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 20 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 15354, NCT01565746
Radium 223 in Castrate Resistant Prostate Cancer Bone Metastases
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: 2013-0933, NCI-2014-02016, NCT02135484
Start Over